RxDoctor Payments Data

Nasser Moukaddem, MD

Internal Medicine · St Petersburg, FLNPI 1124008883

Payments from drug & device makers

$492in general payments, 2019–2025

Across 23 payments — averaging $21.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$172
  • Pfizer$107
  • AbbVie$85
  • Lilly USA, LLC$53
  • Eisai Inc.$20
  • Viiv Healthcare Company$19
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$492100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk8$172
Pfizer3$107
AbbVie(2 entities)5$85
Lilly USA, LLC3$53
Eisai Inc.1$20
Viiv Healthcare Company1$19
Abbott1$18
GSK1$17

How this compares

$492 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$59,336
Medicare patients
187
Services billed
612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide127$172,528
EliquisApixaban102$122,739
BiktarvyBictegrav/Emtricit/Tenofov Ala22$92,450
OdefseyEmtricitab/Rilpiviri/Tenof Ala19$72,604
MounjaroTirzepatide52$53,315
JardianceEmpagliflozin33$50,774
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$42,777
JanuviaSitagliptin Phosphate27$37,619
PrezcobixDarunavir/Cobicistat11$31,402
Budesonide ErBudesonide12$27,825
LinzessLinaclotide22$27,354
FarxigaDapagliflozin Propanediol20$26,338
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$23,139
EntrestoSacubitril/Valsartan17$21,843
TrulicityDulaglutide14$21,478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$172$172,528127 claims
PfizerEliquis$107$122,739102 claims
Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30$53$77,85481 claims
AbbVieLinzess$85$27,35422 claims
GSKTrelegy Ellipta$17$23,13919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →